lan-SOE-pra-zole
BEERS REMS
OTC
Absorption: 80% absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 97%.
Half-Life: Children: 1.2–1.5 hr; Adults: 1.3–1.7 hr (↑ in geriatric patients and patients with impaired hepatic function).
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo)
GI: diarrhea, abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), fundic gland polyps, nausea
GU: acute tubulointerstitial nephritis
Hemat: vitamin B12 deficiency
MS: bone fracture
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR ACUTE TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus
Drug-drug:
H. pylori
eradication to reduce the risk of duodenal ulcer recurrence: 30 mg twice daily with clarithromycin 500 mg twice daily and amoxicillin 1000 mg twice daily for 10–14 days (triple therapy) or 30 mg 3 times daily with 1000 mg amoxicillin 3 times daily for 14 days (dual therapy); Maintenance of healed duodenal ulcers: 15 mg once daily; Short-term treatment of gastric ulcers/healing of NSAID-associated gastric ulcer: 30 mg once daily for up to 8 wk; Risk reduction of NSAID-associated gastric ulcer: 15 mg once daily for up to 12 wk; Short-term treatment of symptomatic GERD: 15 mg once daily for up to 8 wk; Short-term treatment of erosive esophagitis: 30 mg once daily for up to 8 wk (8 additional wk may be necessary); Maintenance of healing of erosive esophagitis: 15 mg once daily; Pathologic hypersecretory conditions: 60 mg once daily initially, up to 90 mg twice daily (daily dose >120 mg should be given in divided doses).Lab Test Considerations:
NDC Code